Compare
BridgeBio Oncology Therapeutics, Inc. vs Biohaven Ltd. vs BGM Group Ltd. vs Arcutis Biotherapeutics, Inc.
| Latest fiscal year | BridgeBio Oncology Therapeutics, Inc. BBOT | Biohaven Ltd. BHVN | BGM Group Ltd. BGM | Arcutis Biotherapeutics, Inc. ARQT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-09-30 | 2025-12-31 |
| Revenue | n/a | n/a | $37.92M | $372.07M |
| Revenue growth (YoY) | n/a | n/a | +51.1% | +123.4% |
| Gross margin | n/a | n/a | 16.6% | 90.1% (computed) |
| Operating margin | n/a | n/a | -33.2% | -3.3% |
| Net margin | n/a | n/a | -52.6% | -4.3% |
| Net income | -$134.04M | -$738.82M | -$19.94M | -$16.14M |
| EPS (Diluted) | -$4.30 | -$6.86 | -$0.18 | -$0.13 |
| Operating cash flow | -$113.89M | -$609.44M | -$2.37M | -$5.62M |
| Free cash flow | -$114.50M | -$610.15M | -$3.94M | -$6.31M |
| Cash & equivalents | $373.69M | $229.96M | $9.82M | $42.91M |
| Total assets | $448.38M | $451.45M | $433.81M | $432.97M |
| Total liabilities | $37.28M | $399.38M | $41.92M | $243.49M |
| Shareholders' equity | $411.10M | $52.07M | $391.90M | $189.48M |
| Return on year-end equity | -32.6% | n/m | -5.1% | -8.5% |
| Shares outstanding | 79.99M | 132.78M | 200.62M | 123.33M |
Revenue, most recent five fiscal years
| Fiscal year | BridgeBio Oncology Therapeutics, Inc. | Biohaven Ltd. | BGM Group Ltd. | Arcutis Biotherapeutics, Inc. |
|---|---|---|---|---|
| Latest | n/a | n/a | $37.92M Ended 2025-09-30 | $372.07M Ended 2025-12-31 |
| 1 year earlier | n/a | n/a | $25.10M Ended 2024-09-30 | $166.54M Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | $46.47M Ended 2023-09-30 | $59.61M Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | $64.86M Ended 2022-09-30 | $3.69M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | $57.10M Ended 2021-09-30 | $0 Ended 2021-12-31 |